Aspirin Reduces Recurrence Risk by 51% in Colorectal Cancer Patients with PIK3CA Mutations: Findings from Nordic Study

The promising results of the ALASCCA study highlight aspirin as a potential breakthrough in colorectal cancer treatment, offering a personalized approach to reduce recurrence risk in a significant proportion of early-stage patients. In this MEDtalk, Professor Anna Martling, Co-Director of Surgery at Karolinska Institute and Karolinska Hospital in Stockholm, Sweden, discusses how the findings could reshape clinical practice for over a third of patients with early-stage colorectal cancer. In 2024, Professor Martling served as the Scientific Director of Life Science at Karolinska Institutet. Her research has received numerous awards. In 2013, Anna Martling received the Swedish Surgical Society´s Great Research Prize. In year 2021 she received the prize “Cancer Researcher of the Year” from The Swedish Cancer Society.